Hypertension as a risk factor of dementia and cognitive decline in the elderly

Japanese Journal of Geriatrics

Volumn 44, Issue 4, 2007, Pages 433-436

  Takechi, Hajime ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

Cognitive decline; Dementia; Hypertension; Risk factor; White matter lesion

Indexed keywords

AGED; ARTICLE; COGNITIVE DEFECT; DEMENTIA; HUMAN; HYPERTENSION; RISK FACTOR;

AGED; COGNITION DISORDERS; DEMENTIA; HUMANS; HYPERTENSION; RISK FACTORS;

EID: 34548314580     PISSN: 03009173     EISSN: None     Source Type: Journal    
DOI: 10.3143/geriatrics.44.433     Document Type: Article

References (22)

1. Launer LJ, Masaki K, Petrovitch H, Foley D, Havlik RJ: The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study. JAMA 1995:274: 1846-1851.
2. Skoog I, Lernfelt B, Landahl S, Palmertz B, Andreasson LA, Nilsson L, et al.: 15-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-1145.
3. Qiu C, Winblad B, Fratiglioni L: The age-dependent relation of blood pressure to cognitive function and dementia. Lancet Neurol 2005:4:487-499.
4. Kivipelto M, Helkala EL, Laakso MP, Hanninen T, Hallikainen M, Alhainen K, et al.; Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 2002; 137: 149-155.
5. Peila R, White LR, Petrovich H, Masaki K, Ross GW, Havlik RJ, et al.: Joint effect of the APOE gene and midlife systolic blood pressure on late-life cognitive impairment; the Honolulu-Asia aging study, Stroke 2001; 32:2882-2889.
6. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, et al.: The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002; 162:2046-2052,
7. Skoog I, Lithell H, Hansson L, Elmfeldt D, Hofman A, Olofsson B, et al.: Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: Study on COgnition and Prognosis in the Elderly (SCOPE). Am J Hypertens 2005; 18; 1052-1059.
8. Peila R, White LR, Masaki K, Petrovitch H, Launer LJ: Reducing the risk of dementia: efficacy of long-term treatment of hypertension. Stroke 2006; 37:1165-1170.
9. Khachaturian AS, Zandi PP, Lyketsos CG, Hayden KM, Skoog I, Norton MC, et al.: Antihypertensive medication use and incident Alzheimer disease: the Cache County Study, Arch Neurol 2006; 63:686-692.
10. Fogari R, Mugellini A, Zoppi A, Marasi G, Pasotti C, Poletti L, et al.: Effects of valsartan compared with enalapril on blood pressure and cognitive function in elderly patients with essential hypertension. Eur J Clin Pharmacol 2004; 59:863-868.
11. Ohrui T, Tomita N, Sato-Nakagawa T, Matsui T, Maruyama M, Niwa K, et al.: Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 2004; 63:1324-1325,
12. de Leeuw FE, de Groot JC, Achten E, Oudkerk M, Ramos LM, Heijboer R, et al.: Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study, The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry 2001; 70:9-14.
13. Liao D, Cooper L, Cai J, Toole JF, Bryan NR, Hutchinson RG, et al.: Presence and severity of cerebral white matter lesions and hypertension, its treatment, and its control, The ARIC Study. Atherosclerosis Risk in Communities Study. Stroke 1996; 27:2262-2270.
14. Dufouil C, de Kersaint-Gilly A, Besancon V, Levy C, Auffray E, Brunnereau L, et al.: Longitudinal study of blood pressure and white matter hyperintensities: the EVA MRI Cohort. Neurology 2001; 56:921-926.
15. de Leeuw FE, deGroot JC, Oudkerk M, Witteman JC, Hofman A, van Gijn J, et al.: Hypertension and cerebral white matter lesions in a prospective cohort study. Brain 2002; 125:765-772.
16. Carmelli D, De Carli C, Swan GE, Jack LM, Reed T, Wolf PA, et al.: Evidence for genetic variance in white matter hyperintensity volume in normal elderly male twins. Stroke 1998; 29:1177-1181.
17. Szolnoki Z, Somogyvari F, Kondacs A, Szabo M, Fodor L, Bene J, et al.: Specific APO E genotypes in combination with the ACE D/D or MTHFR 677TT mutation yield an independent genetic risk of leukoaraiosis. Acta Neurol Scand 2004; 109:222-227.
18. de Leeuw FE, Richard F, de Groot JC, van Duijn CM, Hofman A, Van Gijn J, et al.: Interaction between hypertension, apoE, and cerebral white matter lesions. Stroke 2004; 35:1057-1060.
19. Gunning-Dixon FM, Raz N: The cognitive correlates of white matter abnormalities in normal aging: a quantitative review. Neuropsychology 2000; 14:224-232.
20. Au R, Massaro JM. Wolf PA, Young ME, Beiser A, Seshadri S, et al: Association of white matter hyperintensity volume with decreased cognitive functioning: the Framingham Heart Study. Arch Neurol 2006; 63: 246-250.
21. Hirono N, Kitagaki H, Kazui H, Hashimoto M, Mori E: Impact of white matter changes on clinical manifestation of Alzheimer's disease: A quantitative study. Stroke 2000; 31:2182-2188.
22. Burns JM, Church JA, Johnson DK, Xiong C, Marcus D, Fotenos AF: White matter lesions are prevalent but differentially related with cognition in aging and early Alzheimer disease. Arch Neurol 2005; 62:1870-1876.